
Cosmetic QC Batch Analysis & Release Decision Framework
Analyze cosmetic batches, identify deviations, and generate regulatory-defensible release decisions.
What You Can Do
You'll transform raw QC analytical data into structured batch release decisions that satisfy regulatory requirements. Claude guides you through specification comparison, statistical deviation analysis, root cause tracing, and corrective action planning—turning instrumental results (HPLC, viscosity, pH, microbiology) into clear hold/release recommendations with documented justification for audits and inspections.
Features
automatically compare batch test results against established limits and flag deviations with severity ratings
trace out-of-spec results to formulation, process, raw material, or environmental sources using systematic investigation logic
evaluate 3-month, 6-month, and 12-month stability milestones to assess shelf-life validity and predict degradation patterns
determine whether deviations require formal investigation (CAPA) or fall within normal variation per ICH Q14 principles
review COA data and functional testing results to qualify or reject incoming materials before batch manufacturing
produce regulatory-defensible documentation with statistical justification, risk assessment, and sign-off authority recommendations
identify systemic issues and generate CAPA assignments with closure dates and preventive measures
cross-reference findings against FDA CFR 211, ISO 22716, and EU Cosmetics Regulation requirements
Example Output
Example 1: Out-of-Spec pH Hold Decision
Batch: PROD-2024-0156 | Product: Facial Moisturizer | Specification: pH 5.5–6.5
Test Result: pH 6.8 (deviation: +0.3 units)
Root Cause Analysis:
- Raw material pH drift: Glycerin lot #GM-2024-447 measured pH 7.1 vs. supplier spec 6.8–7.0 (borderline high)
- Formulation calculation: 15% glycerin contribution + other excipient pH accumulation = batch-level excursion
- Process: No buffer adjustment step post-mixing
Recommendation: HOLD for investigation. Deviation exceeds ±0.3 tolerance. Issue CAPA: (1) Reject glycerin lot #GM-2024-447, (2) Implement post-mix pH buffering protocol, (3) Tighten supplier COA acceptance limits.
Example 2: Stability Trend Assessment – Fragrance Intensity Loss
Product: Body Spray | Test Method: Gas Chromatography (GC) Fragrance Assay
| Timepoint | Result | Spec | Status |
|---|---|---|---|
| Day 0 | 98.5% | 95–105% | ✓ Pass |
| 3 mo | 94.2% | 90–105% | ✓ Pass |
| 6 mo | 88.7% | 85–105% | ✓ Pass |
| 12 mo | 81.3% | 80–105% | ✓ Pass (edge) |
Trend Analysis: Linear degradation ~4.5% per 3 months. Projected 24-month level: 72.9% (below 80% limit). Recommendation: Approve 12-month shelf-life; DO NOT extend to 24 months without reformulation (e.g., higher fragrance load or enhanced containment). Document stability projection for regulatory file.
What's Included
- SKILL.md instruction file with structured batch analysis protocol and decision logic:
- Batch Release Decision Template: fill-in memo format with specification comparison, deviation severity matrix, and sign-off sections
- Root Cause Analysis Checklist: systematic investigation prompts (formulation, process, raw materials, environment)
- Stability Trending Worksheet: timepoint-by-timepoint assessment with degradation rate calculation and shelf-life projection
- Regulatory Compliance Checklist: FDA CFR 211, ISO 22716, and EU Cosmetics Regulation reference points for documentation
Who It's For
- Cosmetic chemists and QC analysts evaluating batch data before release
- Formulation scientists managing stability testing programs and shelf-life claims
- Quality assurance managers building CAPA cases and regulatory defense documentation
- Regulatory affairs professionals preparing batch records for inspections and audits
- Manufacturing supervisors determining hold/release decisions for production batches
Best For
- Batch release/hold decision-making for finished cosmetic products
- Specification deviation investigation and root cause analysis
- Stability milestone evaluation (3-month, 6-month, 12-month testing rounds)
- Corrective and preventive action (CAPA) case development and closure
- Raw material vendor COA review and acceptance/rejection decisions
- Regulatory-defensible batch documentation for FDA and international audits







